INTERMEDIATE RISK ACUTE MYELOID LEUKEMIA
Clinical trials for INTERMEDIATE RISK ACUTE MYELOID LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new INTERMEDIATE RISK ACUTE MYELOID LEUKEMIA trials appear
Sign up with your email to follow new studies for INTERMEDIATE RISK ACUTE MYELOID LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo aims to improve leukemia treatment before transplant
Disease control Recruiting nowThis study is for adults with a certain type of acute myeloid leukemia (AML) who are in remission and planning a stem cell transplant. It compares a combination of two drugs, venetoclax and azacitidine, against standard high-dose chemotherapy as a 'consolidation' step before the …
Matched conditions: INTERMEDIATE RISK ACUTE MYELOID LEUKEMIA
Phase: PHASE2 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New drug cocktail may replace bone marrow transplant for some leukemia patients
Disease control Recruiting nowThis study tests a new treatment for adults with a specific type of acute myeloid leukemia (FLT3-ITD AML). The goal is to see if a combination of targeted drugs (gilteritinib, venetoclax, azacitidine) followed by high-dose chemotherapy can control the disease well enough to avoid…
Matched conditions: INTERMEDIATE RISK ACUTE MYELOID LEUKEMIA
Phase: PHASE2 • Sponsor: First Affiliated Hospital of Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC